US 12,109,178 B2
Bupropion as a modulator of drug activity
Herriot Tabuteau, New York, NY (US)
Assigned to ANTECIP BIOVENTURES II LLC, New York, NY (US)
Filed by ANTECIP BIOVENTURES II LLC, New York, NY (US)
Filed on Aug. 22, 2022, as Appl. No. 17/821,342.
Application 17/821,342 is a continuation of application No. 17/373,299, filed on Jul. 12, 2021, granted, now 11,426,370.
Application 17/821,342 is a continuation of application No. PCT/US2021/024718, filed on Mar. 29, 2021.
Application 17/373,299 is a continuation in part of application No. 17/099,226, filed on Nov. 16, 2020, granted, now 11,058,648, issued on Jul. 13, 2021.
Application 17/099,226 is a continuation in part of application No. 16/894,713, filed on Jun. 5, 2020, granted, now 10,898,453, issued on Jan. 26, 2021.
Application 17/099,226 is a continuation in part of application No. 16/852,939, filed on Apr. 20, 2020, abandoned.
Application 16/852,939 is a continuation in part of application No. PCT/US2020/012612, filed on Jan. 7, 2020.
Application 17/099,226 is a continuation in part of application No. 16/129,531, filed on Sep. 12, 2018, granted, now 10,881,624, issued on Jan. 5, 2021.
Application 16/129,531 is a continuation of application No. 15/691,532, filed on Aug. 30, 2017, granted, now 10,092,560, issued on Oct. 9, 2018.
Application 15/691,532 is a continuation of application No. 15/236,290, filed on Aug. 12, 2016, granted, now 9,763,932, issued on Sep. 19, 2017.
Application 15/236,290 is a continuation in part of application No. 15/213,283, filed on Jul. 18, 2016, abandoned.
Application 15/236,290 is a continuation in part of application No. 15/130,807, filed on Apr. 15, 2016, granted, now 9,421,176, issued on Aug. 23, 2016.
Application 15/213,283 is a continuation in part of application No. 15/057,983, filed on Mar. 1, 2016, granted, now 9,408,815, issued on Aug. 9, 2016.
Application 15/236,290 is a continuation in part of application No. 14/997,316, filed on Jan. 15, 2016, granted, now 9,457,025, issued on Oct. 4, 2016.
Application 15/130,807 is a continuation in part of application No. 14/878,998, filed on Oct. 8, 2015, granted, now 9,314,462, issued on Apr. 19, 2016.
Application 15/057,983 is a continuation in part of application No. 14/863,284, filed on Sep. 23, 2015, granted, now 9,278,095, issued on Mar. 8, 2016.
Application 14/878,998 is a continuation of application No. 14/550,618, filed on Nov. 21, 2014, granted, now 9,198,905, issued on Dec. 1, 2015.
Application 14/550,618 is a continuation in part of application No. PCT/US2014/064184, filed on Nov. 5, 2014.
Claims priority of provisional application 63/032,517, filed on May 29, 2020.
Claims priority of provisional application 63/016,178, filed on Apr. 27, 2020.
Claims priority of provisional application 63/002,132, filed on Mar. 30, 2020.
Claims priority of provisional application 62/948,803, filed on Dec. 16, 2019.
Claims priority of provisional application 62/856,962, filed on Jun. 4, 2019.
Claims priority of provisional application 62/789,451, filed on Jan. 7, 2019.
Claims priority of provisional application 62/789,431, filed on Jan. 7, 2019.
Claims priority of provisional application 62/789,488, filed on Jan. 7, 2019.
Claims priority of provisional application 62/789,446, filed on Jan. 7, 2019.
Claims priority of provisional application 62/336,533, filed on May 13, 2016.
Claims priority of provisional application 62/323,438, filed on Apr. 15, 2016.
Claims priority of provisional application 62/313,620, filed on Mar. 25, 2016.
Claims priority of provisional application 62/313,067, filed on Mar. 24, 2016.
Claims priority of provisional application 61/900,354, filed on Nov. 5, 2013.
Prior Publication US 2023/0045675 A1, Feb. 9, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/138 (2006.01); A61K 9/00 (2006.01); A61K 31/137 (2006.01); A61K 31/485 (2006.01); A61P 25/24 (2006.01)
CPC A61K 31/138 (2013.01) [A61K 9/0053 (2013.01); A61K 31/137 (2013.01); A61K 31/485 (2013.01); A61P 25/24 (2018.01)] 18 Claims
OG exemplary drawing
 
1. A method of treating major depressive disorder, comprising orally administering a dosage form once a day or twice a day to a human patient in need thereof, wherein the dosage form contains about 40 mg to about 50 mg of a dextromethorphan salt, or a molar equivalent amount of the free base form of dextromethorphan, and about 100 mg to about 110 mg of bupropion hydrochloride, or a molar equivalent amount of another salt form or the free base form of bupropion.